Cancer Drug Approval Sends Stock Buzzing

Heads up, stock-watchers: UroGen just got the green light from the FDA for its new bladder cancer treatment, and the stock popped 9% right after. Instead of surgery, patients can now get a weekly treatment—way less hassle. Wall Street’s suddenly super optimistic, with some calling for the stock to nearly triple. The big twist? The FDA said yes even after a panel said no, showing they’ll bend the rules for much-needed meds. Retail investors are hyped, and chatter’s heating up! #StockMarket #FDAApproval #CancerTreatment #Business #Market